vs
Side-by-side financial comparison of FIBROGEN INC (KYNB) and SYPRIS SOLUTIONS INC (SYPR). Click either name above to swap in a different company.
SYPRIS SOLUTIONS INC is the larger business by last-quarter revenue ($30.3M vs $25.4M, roughly 1.2× FIBROGEN INC). SYPRIS SOLUTIONS INC runs the higher net margin — -12.9% vs -129.8%, a 116.9% gap on every dollar of revenue. On growth, SYPRIS SOLUTIONS INC posted the faster year-over-year revenue change (-9.5% vs -29.9%). SYPRIS SOLUTIONS INC produced more free cash flow last quarter ($-1.5M vs $-59.3M). Over the past eight quarters, SYPRIS SOLUTIONS INC's revenue compounded faster (-7.7% CAGR vs -7.8%).
FibroGen Inc. is a biopharmaceutical firm developing and commercializing innovative therapies for unmet medical needs, targeting fibrotic diseases, anemia and cancer. Its lead product roxadustat is approved in multiple markets including China and Japan, serving patients across key therapeutic segments.
Sypris Solutions Inc. is a U.S.-headquartered provider of highly engineered components and specialized technical services, primarily serving aerospace, defense, automotive and commercial industrial markets. It delivers custom manufacturing, performance testing, and value-added engineering support for mission-critical systems and parts for global enterprise clients.
KYNB vs SYPR — Head-to-Head
Income Statement — Q1 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.4M | $30.3M |
| Net Profit | $-32.9M | $-3.9M |
| Gross Margin | 15.9% | 4.6% |
| Operating Margin | -193.9% | -10.9% |
| Net Margin | -129.8% | -12.9% |
| Revenue YoY | -29.9% | -9.5% |
| Net Profit YoY | 57.1% | -2992.6% |
| EPS (diluted) | $-0.33 | $-0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $30.3M | ||
| Q3 25 | — | $28.7M | ||
| Q2 25 | — | $31.4M | ||
| Q1 25 | — | $29.5M | ||
| Q4 24 | — | $33.4M | ||
| Q3 24 | — | $35.7M | ||
| Q2 24 | — | $35.5M | ||
| Q1 24 | $25.4M | $35.6M |
| Q4 25 | — | $-3.9M | ||
| Q3 25 | — | $517.0K | ||
| Q2 25 | — | $-2.1M | ||
| Q1 25 | — | $-899.0K | ||
| Q4 24 | — | $135.0K | ||
| Q3 24 | — | $390.0K | ||
| Q2 24 | — | $16.0K | ||
| Q1 24 | $-32.9M | $-2.2M |
| Q4 25 | — | 4.6% | ||
| Q3 25 | — | 7.2% | ||
| Q2 25 | — | 8.2% | ||
| Q1 25 | — | 11.4% | ||
| Q4 24 | — | 16.1% | ||
| Q3 24 | — | 16.8% | ||
| Q2 24 | — | 15.9% | ||
| Q1 24 | 15.9% | 8.1% |
| Q4 25 | — | -10.9% | ||
| Q3 25 | — | -6.1% | ||
| Q2 25 | — | -4.6% | ||
| Q1 25 | — | -0.4% | ||
| Q4 24 | — | 3.9% | ||
| Q3 24 | — | 4.8% | ||
| Q2 24 | — | 3.6% | ||
| Q1 24 | -193.9% | -3.9% |
| Q4 25 | — | -12.9% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | — | -6.5% | ||
| Q1 25 | — | -3.0% | ||
| Q4 24 | — | 0.4% | ||
| Q3 24 | — | 1.1% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | -129.8% | -6.2% |
| Q4 25 | — | $-0.17 | ||
| Q3 25 | — | $0.02 | ||
| Q2 25 | — | $-0.09 | ||
| Q1 25 | — | $-0.04 | ||
| Q4 24 | — | $0.00 | ||
| Q3 24 | — | $0.02 | ||
| Q2 24 | — | $0.00 | ||
| Q1 24 | $-0.33 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.6M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-228.1M | $17.8M |
| Total Assets | $365.9M | $107.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $177.6M | — |
| Q4 25 | — | $17.8M | ||
| Q3 25 | — | $20.0M | ||
| Q2 25 | — | $18.7M | ||
| Q1 25 | — | $19.0M | ||
| Q4 24 | — | $19.6M | ||
| Q3 24 | — | $18.2M | ||
| Q2 24 | — | $19.0M | ||
| Q1 24 | $-228.1M | $20.8M |
| Q4 25 | — | $107.8M | ||
| Q3 25 | — | $112.5M | ||
| Q2 25 | — | $105.8M | ||
| Q1 25 | — | $110.2M | ||
| Q4 24 | — | $119.4M | ||
| Q3 24 | — | $121.6M | ||
| Q2 24 | — | $124.2M | ||
| Q1 24 | $365.9M | $129.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-59.3M | $-1.1M |
| Free Cash FlowOCF − Capex | $-59.3M | $-1.5M |
| FCF MarginFCF / Revenue | -233.9% | -5.0% |
| Capex IntensityCapex / Revenue | 0.1% | 1.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-274.7M | $-6.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-1.1M | ||
| Q3 25 | — | $-178.0K | ||
| Q2 25 | — | $1.1M | ||
| Q1 25 | — | $-5.5M | ||
| Q4 24 | — | $2.3M | ||
| Q3 24 | — | $-4.8M | ||
| Q2 24 | — | $6.2M | ||
| Q1 24 | $-59.3M | $-1.7M |
| Q4 25 | — | $-1.5M | ||
| Q3 25 | — | $-390.0K | ||
| Q2 25 | — | $941.0K | ||
| Q1 25 | — | $-5.5M | ||
| Q4 24 | — | $1.9M | ||
| Q3 24 | — | $-4.9M | ||
| Q2 24 | — | $6.0M | ||
| Q1 24 | $-59.3M | $-2.0M |
| Q4 25 | — | -5.0% | ||
| Q3 25 | — | -1.4% | ||
| Q2 25 | — | 3.0% | ||
| Q1 25 | — | -18.8% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | — | -13.8% | ||
| Q2 24 | — | 16.8% | ||
| Q1 24 | -233.9% | -5.7% |
| Q4 25 | — | 1.3% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 1.2% | ||
| Q3 24 | — | 0.4% | ||
| Q2 24 | — | 0.5% | ||
| Q1 24 | 0.1% | 0.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | -0.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 17.13× | ||
| Q3 24 | — | -12.21× | ||
| Q2 24 | — | 385.25× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KYNB
| Drug Product Revenue | $24.5M | 97% |
| Other | $878.0K | 3% |
SYPR
| Sypris Electronics | $17.7M | 59% |
| Transferred At Point In Time | $12.5M | 41% |
